Intra-Cellular Therapies (ITCI)
NASDAQ:ITCI
Holding ITCI?
Track your performance easily

Intra-Cellular Therapies (ITCI) Ownership - Who Owns Intra-Cellular Therapies?

884 Followers

Intra-Cellular Therapies (ITCI) Ownership Overview

1.24%31.00%5.55%13.35%48.86%
5.55% Other Institutional Investors
13.35% ETFs
48.86% Public Companies and Individual Investors
The ownership structure of Intra-Cellular Therapies (ITCI) stock is a mix of institutional, retail, and individual investors. Approximately 49.90% of the company’s stock is owned by Institutional Investors, 1.24% is owned by Insiders, and 48.86% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Aug 20, 2024
Mark Neumann
Evp & Cco
xxxxxxxxxxxxx
$1405047
Jun 25, 2024
Rory Riggs
Director
xxxxxxxxxxxxx
$337193
Feb 28, 2024
xxxxxxxxxxxxx
$1458650
Feb 27, 2024
Joel Marcus
Director
xxxxxxxxxxxxx
$1808253

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
9,058,978Institution8.54%829,530,615
8,633,423Institution8.14%790,562,544
4,774,087Institution4.50%437,163,147
2,934,866Institution2.77%268,745,680
2,067,410Institution1.95%189,312,734
1,716,407Institution1.62%157,171,389
1,695,662Institution1.60%155,271,769
1,168,640Institution1.10%107,012,365
1,102,027Institution1.04%100,912,612
1,070,329Insider1.01%98,010,027

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
8,633,423Institution8.14%790,562,544
4,774,087Institution4.50%437,163,147
2,067,410Institution1.95%189,312,734
1,695,662Institution1.60%155,271,769
1,168,640Institution1.10%107,012,365
1,102,027Institution1.04%100,912,612
1,028,215Institution0.97%94,153,648
832,596Institution0.79%76,240,816
773,424Institution0.73%70,822,436
694,609Institution0.66%63,605,346

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,210,725Institution3.03%234,928,748
2,512,663Institution2.37%183,851,552
1,476,164Institution1.39%108,010,920
1,385,660Institution1.31%101,388,742
693,812Institution0.65%63,532,365
567,300Institution0.54%51,947,661
523,242Institution0.49%47,913,270
475,384Institution0.45%43,397,805
365,924Institution0.35%33,507,661
333,768Institution0.31%30,563,136

FAQ

Who Owns Intra-Cellular Therapies (ITCI)?
According to the latest TipRanks data, approximately 5.55% of the company's stock is held by institutional investors, 1.24% is held by insiders, and 48.86% is held by retail investors.
    What percentage of Intra-Cellular Therapies (ITCI) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 5.55% of Intra-Cellular Therapies (ITCI) stock is held by institutional investors.
      What percentage of Intra-Cellular Therapies (ITCI) stock is held by retail investors?
      According to the latest TipRanks data, approximately 48.86% of Intra-Cellular Therapies (ITCI) stock is held by retail investors.
        Who owns the most shares of Intra-Cellular Therapies (ITCI)?
        Vanguard owns the most shares of Intra-Cellular Therapies (ITCI).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis